Sagimet Biosciences (STU:0O2) YoY EBITDA Growth: 19.63% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:0O2 Sagimet Biosciences Inc STU:0O2
18 GF Score
Price €8.12
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Sagimet Biosciences YoY EBITDA Growth?

Sagimet Biosciences STU:0O2 -0.98% 18 YoY EBITDA Growth is 19.63% as of Jun. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 18/100 (Significantly Overvalued). The stock has 4 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Sagimet Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 19.63%.

Sagimet Biosciences's EBITDA per Share for the three months ended in Jun. 2026 was €-0.26.

Sagimet Biosciences YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences YoY EBITDA Growth Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -124.94 -39.60 -103.86 38.44 9.46

Sagimet Biosciences Quarterly Data
Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.22 20.68 47.40 45.53 19.63
STU:0O2
18GF Score
Sagimet Biosciences Inc STU:0O2
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Sagimet Biosciences's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-1.502--1.659)/ | -1.659 |
=9.46 %

Sagimet Biosciences's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.258--0.321)/ | -0.321 |
=19.63 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 19.63% mean?
Sagimet Biosciences (STU:0O2) has a YoY EBITDA Growth of 19.63% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Sagimet Biosciences and its competitors.
Is Sagimet Biosciences' YoY EBITDA Growth too high?
Sagimet Biosciences' current YoY EBITDA Growth is 19.63%. Overall, Sagimet Biosciences has a GF Score™ of 18/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' YoY EBITDA Growth compare to CABA and OVID?
Sagimet Biosciences' YoY EBITDA Growth of 19.63% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Sagimet Biosciences and its competitors. Sagimet Biosciences's current YoY EBITDA Growth is 19.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Sagimet Biosciences (STU:0O2) is currently considered Significantly Overvalued. The current YoY EBITDA Growth is 19.63%. Sagimet Biosciences' overall GF Score™ is 18/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current YoY EBITDA Growth is 19.63% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
18GF Score

Get the complete analysis for STU:0O2

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€8.12
Price